Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052776 | 0.94 | TSHR (0.59) | TSHRGAAKMT2AKDM4EMAPK14 | |
| SCHEMBL20218944 | 0.90 | LTB4R2 (0.62) | TSHRGAAKMT2AMEN1NPC1 | |
| SCHEMBL3060251 | 0.90 | TSHR (0.71) | TSHRGAAKMT2AKDM4EMAPK14 | |
| SCHEMBL12031549 | 0.87 | NPC1 (0.67) | TSHRGAAKMT2AMEN1NPC1 | |
| SCHEMBL3053543 | 0.86 | TSHR (0.59) | TSHRGAAKMT2AKDM4EMAPK14 | |
| SCHEMBL3059878 | 0.85 | MEN1 (0.65) | TSHRGAAKMT2AKDM4EMAPK14 | |
| SCHEMBL18464136 | 0.84 | TSHR (0.54) | TSHRGAAKMT2AKDM4EMAPK14 | |
| SCHEMBL4237595 | 0.83 | CNR2 (0.58) | TSHRGAAKMT2AMEN1NPC1 | |
| SCHEMBL18464008 | 0.83 | TSHR (0.55) | TSHRGAAKMT2AKDM4EMAPK14 | |
| SCHEMBL3059551 | 0.82 | L3MBTL1 (0.62) | TSHRGAAKMT2AKDM4EMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330259-A1 | 1,3,4-OXADIAZOLE AMIDE DERIVATIVE COMPOUND AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-06 | — | — | EP | disclosed |
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| CN-101405268-A | Amide derivatives and their use for the treatment of protein-related diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | TSHR 384/4885GAA 1212/4885KMT2A 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.